Viscosupplementation Market To Observe A CAGR Of 8.2% till 2027 | Anika Therapeutics Inc., Seikagaku Corporation, Ferring Pharmaceuticals, etc | CMI
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global Viscosupplementation Market, by Treatment (Single Injection Treatment Cycle, Three Injection Treatment Cycle, and Five Injection Treatment Cycle) by Application (Knee Osteoarthritis, Hip Osteoarthritis, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2,524.8 Mn in 2019 and is expected to surpass US$ 4,738.8 Mn by 2027, witnessing a CAGR of 8.2% over the forecast period (2019-2027) as highlighted in a new report published by Coherent Market Insights.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/197
Manufacturers are engaged in developing new viscosupplementation products to improve osteoarthritis treatment, which, in turn, has led to an increase in product launches and approvals. These factors are expected to boost the global viscosupplementation market growth. For instance, in December 2019, Fidia Pharma USA Inc., a wholly-owned subsidiary of Fidia Pharmaceutics S.P.A., launched TRILURON (sodium hyaluronate) in the U.S. and also received the U.S. Food and Drug Administration’s (FDA) Pre-Market Approval in April 2019. The TRILURON treatment cycle consists of three injections given at weekly intervals.
Moreover, in 2015, Bioventus, a global leader in orthobiologic solutions, launched SUPARTZ FX, a five–injection, hyaluronic acid (HA) product for the treatment of knee osteoarthritis pain. Furthermore, in 2015, OrthogenRx Inc. received the U.S. Food and Drug Administration’s (FDA) approval for its product GenVisc 850 (sodium hyaluronate). GenVisc 850 is used for the treatment of patients suffering from knee pain associated with osteoarthritis (OA).
Several organizations, and institutions are engaged in raising awareness regarding osteoarthritis, and providing information regarding its symptoms and prevention. This is also expected to positively impact growth of the global viscosupplementation market. For instance, in April 2019, the International Association for Study of Pain initiated ‘Real Women, Real Pain’ awareness campaign for pain and pain-related issues affecting women across the world. Furthermore, in May, Osteoarthritis Action Alliance (OAAA) launched ‘StandUP2OA’, a new comprehensive campaign focused on spreading awareness about osteoarthritis and its prevention.
Quick Buy – Viscosupplementation Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/197
Manufacturers are focused on strengthening their distribution network by signing distributive agreements in order to increase the supply of their products all over the world. This, in turn, is expected to propel the global viscosupplementation market growth. For instance, in February 2018, Bioventus extended its distribution agreement with Seikagaku Corporation to distribute its product, SUPARTZ FX, a five-injection hyaluronic acid (HA) product, in the U.S. Moreover, in October 2017, Mylan N.V. and Unimedic Group entered into an exclusive distribution agreement spanning over 5 years, for distribution of its product ‘Suplasyn’ in all Nordic countries.
Key takeaways of the global viscosupplementation market:
- The global viscosupplementation market is expected to exhibit a CAGR of 8.2% over the forecast period (2019-2027), owing to frequent product approvals and launches, as well as adoption of inorganic growth strategies such as collaborations and partnerships among key players.
- On the basis of treatment, the three injection treatment cycle segment is expected to hold a dominant position in the global viscosupplementation market over the forecast period, owing to product availability, and increasing product approvals and launches of three injection treatment cycle viscosupplementation products.
- For instance, all the major players including Anika Therapeutics Inc., Seikagaku Corporation, Ferring Pharmaceuticals, Bioventus, Fidia Farmaceutici S.P.A, and others offers three injection treatment cycle products.
- Based on application, the knee osteoarthritis segment is expected to witness significant growth owing to increasing incidence of most common orthopedic disorder such as knee and hip osteoarthritis.
- Some of the major players involved in the global viscosupplementation market are Anika Therapeutics Inc., Seikagaku Corporation, Ferring Pharmaceuticals, Bioventus, Fidia Farmaceutici S.P.A., Mylan N.V., Sanofi S.A., OrthogenRx, Teva Pharmaceutical Industries Ltd, and Johnson & Johnson.
Browse 24 Market Data Tables, and 26 Figures spread through 160 Pages and in-depth TOC on Global Viscosupplementation Market, by Treatment (Single Injection Treatment Cycle, Three Injection Treatment Cycle, Five Injection Treatment Cycle) by Application (Knee Osteoarthritis, Hip Osteoarthritis, and others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2027
To know the latest trends and insights prevalent in the viscosupplementation market press Release, click the link below: https://www.coherentmarketinsights.com/press-release/viscosupplementation-market-to-surpass-us-47388-mn-by-2027-2722
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment
- Market Snippet, By Application
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Industry Trend
- Mergers and Acquisitions
- Technology Overview
- Promotion Initiatives
- Global Viscosupplementation Market, By Treatment, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Single Injection Treatment Cycle
- Three Injection Treatment Cycle
- Five Injection Treatment Cycle
- Introduction
- Global Viscosupplementation Market, By Application, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Knee Osteoarthritis
- Hip Osteoarthritis
- Others
- Introduction
- Global Viscosupplementation Market, By Region, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 – 2027
- North America
- Market Size and Forecast, By Treatment, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Application, 20176– 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Treatment, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Application, 20176– 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Treatment, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Application, 20176– 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Treatment, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Application, 20176– 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, By Treatment, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Application, 20176– 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Treatment, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Application, 20176– 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Anika Therapeutics Inc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Seikagaku Corporation
- Ferring Pharmaceuticals
- Bioventus
- Fidia Farmaceutici S.P.A.
- Mylan N.V.
- Sanofi S.A.
- ORTHOGENRX
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson
- Anika Therapeutics Inc
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
